近日,一品红发布公告,拟出售参股公司美国Arthrosi Therapeutics, Inc.(以下简称Arthrosi)公司股权。目前一品红通过全资子公司瑞腾生物(香港)有限公司持有Arthrosi 13.45%的股权。此次交易的核心标的,是Arthrosi旗下处于Ⅲ期临床试验阶段的痛风创新药AR882(中文通用名:氘泊替诺雷)。尽管一品红明确表示,交易将产生积极影响并同步推出股份回购方案,但...
Source Link近日,一品红发布公告,拟出售参股公司美国Arthrosi Therapeutics, Inc.(以下简称Arthrosi)公司股权。目前一品红通过全资子公司瑞腾生物(香港)有限公司持有Arthrosi 13.45%的股权。此次交易的核心标的,是Arthrosi旗下处于Ⅲ期临床试验阶段的痛风创新药AR882(中文通用名:氘泊替诺雷)。尽管一品红明确表示,交易将产生积极影响并同步推出股份回购方案,但...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.